Yunchun Li, Yue Wang, Jun Fang Zhong, Qizhu Su, Liumei Ding
Department of Laboratory Center, Affiliated Hospital of Fudan University, Jin shan Hospital, Shanghai, China
Guanghua Integrated Hospital, Shanghai, China.
Ann Clin Lab Sci. 2018 Jan;48(1):63-68.
To investigate the serum level of Myeloid-Related Protein 8/14 complex (MRP8/14) and to predict and monitor the response to biologic treatment in rheumatoid arthritis (RA) patients.
Each patient underwent clinical examination and blood sampling for assessment of serum high-sensitivity C-reactive protein (hs-CRP) levels, erythrocyte sedimentation rate (ESR), rheumatoid factors (RF), anti-cyclic citrullinated protein antibodies (anti-CCP), and serum concentrations of MRP8/14 protein complexes (myeloid-related proteins, MRP8/14) were measured at baseline, and weeks 4 and 12 (after initiation of treatment).
Serum MRP8/14 protein complex levels correlated with DAS28 and anti-CCP antibody. MRP8/14 protein complex levels decreased significantly after 12 weeks treatment with biological therapy: mono-rhTNFR-Fc active group. rhTNFR-Fc plus methotrexate (MTX) decreased MRP8/14 protein complex levels from 11839±1849 ng/ml to 5423±1130 ng/ml (<0.01) a reduction of 54.2% compared with 32.9% in the rhTNFR-Fc group.
MRP8/14 protein complex levels were increased in active stage RA patients. MRP8/14 levels were decreased with rhTNFR-Fc treatment, suggesting serum concentrations of MRP8/14 protein complex might be a promising biomarker to predict responses to biological therapy in active RA patients at baseline and could be used to monitor responses to treatment across different mechanisms of action.
研究髓系相关蛋白8/14复合物（MRP8/14）的血清水平，并预测和监测类风湿关节炎（RA）患者对生物治疗的反应。
每位患者均接受临床检查和血液采样，以评估血清高敏C反应蛋白（hs-CRP）水平、红细胞沉降率（ESR）、类风湿因子（RF）、抗环瓜氨酸化蛋白抗体（抗CCP），并在基线、治疗第4周和第12周（治疗开始后）测量血清MRP8/14蛋白复合物（髓系相关蛋白，MRP8/14）的浓度。
血清MRP8/14蛋白复合物水平与疾病活动评分28（DAS28）和抗CCP抗体相关。生物治疗12周后，MRP8/14蛋白复合物水平显著下降：单药重组人肿瘤坏死因子受体-Fc（rhTNFR-Fc）活性组。rhTNFR-Fc联合甲氨蝶呤（MTX）使MRP8/14蛋白复合物水平从11839±1849 ng/ml降至5423±1130 ng/ml（<0.01），降低了54.2%，而rhTNFR-Fc组为32.9%。
活动期RA患者的MRP8/14蛋白复合物水平升高。rhTNFR-Fc治疗可降低MRP8/14水平，提示血清MRP8/14蛋白复合物浓度可能是预测活动期RA患者基线时对生物治疗反应的有前景的生物标志物，可用于监测不同作用机制治疗的反应。
